Drug Trial Radar · NCT07220538
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Nov 28, 2025
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Dr. Willmar Schwabe GmbH & Co. KGIndustry
- Sponsor type
- Industry
- Collaborators
- Beijing Tiantan Hospital
- First posted
- Oct 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if Extract of Ginkgo Biloba Leaves Tablets help improve thinking and memory in people aged 55 years and older who had an ischemic stroke (a type of stroke caused by a blocked blood vessel in the brain). It will also look at how safe the Extract of Ginkgo Biloba Leaves Tablets are. The main questions it aims to answer are: * Do the Extract of Ginkgo Biloba Leaves Tablets help people with memory or thinking problems after an ischemic stroke? * What medical problems do people have when taking the Extract of Ginkgo Biloba Leaves Tablets ? Researchers will compare people who take the Extract of Ginkgo Biloba Leaves Tablets along with their usual post-stroke treatment to people who only receive their usual post-stroke treatment. Participants will: * Have had an ischemic stroke confirmed by MRI (Magnet Resonance Imaging, a magnetic scan that helps seeing inside the body in great detail) 7 to 14 days before joining the study * Take Extract of Ginkgo Biloba Leaves Tablets (240 mg per day) in addition to usual post-stroke treatment for 12 months, or receive only usual post-stroke treatment for 12 months * Be treated initially at hospitals across China * Visit the clinic 4, 26, and 52 weeks following the baseline for checkups and tests, and receive follow-up calls after 12 and 38 weeks.
Conditions
- Ischemic Stroke Hospitalized
- Impairment, Cognitive
Interventions
Extract of Ginkgo Biloba Leaves Tablets 240 mg (2 x 40 mg, t.i.d.)Drug
3 x 2 film-coated tablets with 40 mg Extract of Ginkgo Biloba Leaves Tablets daily for 52 weeks plus standard of care in accordance with treatment guidelines
Standard of care (SoC) GroupOther
Individualized therapy in accordance with treatment guideline from the Chinese Stroke Association
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Montreal Cognitive Assessment (MoCA) Total ScoreTime frame: From baseline to Week 26 (Visit 4) and Week 52 (Visit 6)
- Change in Cognitive Function Using Trail Making Test (TMT) Parts A and BTime frame: Change from baseline to Week 26 (Visit 4) and Week 52 (Visit 6)
- Change in Cognitive Processing Speed Using Symbol Digit Modalities Test (SDMT)Time frame: Change from baseline to Week 26 (Visit 4) and Week 52 (Visit 6)
- Change in Verbal Fluency Performance Using Verbal Fluency Test (VFT)Time frame: Change from baseline to Week 26 (Visit 4) and Week 52 (Visit 6)
- Change in Clinical Global Impression of Change Using ADCS-CGIC (Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change)Time frame: Change from baseline to Week 26 (Visit 4) and Week 52 (Visit 6)
- Change in Neurological Impairment Using National Institutes of Health Stroke Scale (NIHSS)Time frame: Change from Baseline to Week 4 (Visit 1), Week 26 (Visit 4) and Week 52 (Visit 6)
- Change in Neurological Impairment Using Modified Rankin Scale (mRS)Time frame: Change from Baseline to Week 4 (Visit 1), Week 26 (Visit 4) and Week 52 (Visit 6)
- Any new stroke event (ischemic stroke or hemorrhagic stroke) at Week 4, Week 12, Week 26, Week 38 and Week 52.Time frame: Week 4, Week 12, Week 26, Week 38 and Week 52
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
The People's Hospital of Anyang City
Anyang, China
Baotou Central Hospital
Baotou, China
Tiantan Hospital
Beijing, China
Benxi Central Hospital
Benxi, China
The First People's Hospital of Chenzhou
Chenzhou, China
Affiliated Hospital of Chifeng University
Chifeng, China
Affiliated Zhongshan Hospital of Dalian University
Dalian, China
Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital)
Dalian, China
Dalian Lvshunkou District Traditional Chinese Medicine Hospital
Dalian, China
Dalian University Affiliated Xinhua Hospital
Dalian, China
The 2nd Affiliated Hospital of Harbin Medical University
Harbin, China
Affiliated Hospital of Hebei University
Hebei, China
The Second Hospital of Hebei Medical University
Hebei, China
The Second Affiliated Hospital of Henan University of Science and Technology
Henan, China
Huizhou First Hospital
Huizhou, China
The First Affiliated Hospital of Jiamusi University
Jiamusi, China
China-Japan Union Hospital of Jilin University
Jilin City, China
Jiujiang No.1 People's Hospital
Jiujiang, China
Liaocheng People´s Hospital
Liaocheng, China
Liuzhou Workers´ Hospital
Liuzhou, China
Luoyang Central Hospital
Luoyang, China
Nanning First People's Hospital
Nanning, China
Puyang Oilfield General Hospital
Pujiang, China
Second Hospital of Shanxi Medical University
Shanxi, China
Shanxi Cardiovascular Hospital
Shanxi, China
The First People's Hospital Of Shenyang
Shenyang, China
The People's Hospital of Liaoning Province
Shenyang, China
Siping City Central People's Hospital
Siping, China
Suining Central Hospital
Suining, China
Weifang People´s Hospiztal
Weifang, China
Zhongnan Hospital of Wuhan University
Wuhan, China
Yantaishan Hospital
Yantai, China
Zhumadian Central Hospital
Zhumadian, China
Zibo Municipal Hospital
Zibo, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.